Ocular Melanoma Clinical Trial
Official title:
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
The purpose of this study is to determine the feasibility and tolerability of neo-adjuvant/adjuvant Darovasertib on uveal melanoma patients. Who is it for? Patients may be eligible to join this study with high-risk uveal melanoma and planned to undergo enucleation Study details: Eligible patients will undergo up to 4 weeks of treatment with Darovasertib (300mg, twice a day as a starting dose) and once determiend safe then up to 6 months after fulfilling inclusion/exclusion criteria and consent. Select patients will undergo adjuvant treatment for 6 months based on their initial response. It is hoped that this research will provide insight into the safety and tolerability of Darovasertib. Furthermore, it aims to document the pharmacodynamic and pharmacokinectic effects of Darovasertib on uveal melanoma patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04364230 -
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
|
Phase 1/Phase 2 | |
| Completed |
NCT01200238 -
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
|
Phase 2 | |
| Completed |
NCT02858869 -
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
|
Phase 1 | |
| Completed |
NCT01355120 -
THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease
|
Phase 2 | |
| Recruiting |
NCT05524935 -
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
|
Phase 2 | |
| Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
| Recruiting |
NCT02909517 -
The Role of Inflammation in Ocular Tumours
|
||
| Withdrawn |
NCT00621439 -
Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye
|
N/A | |
| Terminated |
NCT00346372 -
Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
|
||
| Recruiting |
NCT03172299 -
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma
|
Phase 3 | |
| Not yet recruiting |
NCT06432660 -
Eye Plaque Brachytherapy for Ocular Melanoma
|
||
| Completed |
NCT01893099 -
Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
|
Phase 1 | |
| Completed |
NCT00351728 -
Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone
|
N/A | |
| Active, not recruiting |
NCT03528408 -
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
|
Phase 2 | |
| Completed |
NCT03052127 -
Study in Subjects With Small Primary Choroidal Melanoma
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01930968 -
Definity for Ultrasound of Intraocular Tumors
|
||
| Recruiting |
NCT00168870 -
Study of Metastatic Ocular Melanoma
|
Phase 2 | |
| Completed |
NCT02519322 -
Neoadjuvant and Adjuvant Checkpoint Blockade
|
Phase 2 | |
| Recruiting |
NCT06007690 -
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
|
Phase 3 | |
| Active, not recruiting |
NCT04417530 -
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
|
Phase 2 |